RecruitingNot ApplicableNCT07276438

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

MRI- or CT-Guidance and Online Adaptation With Stereotactic Radiotherapy for Prostate Cancer (MANTICORE)


Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

186 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of the body (localized). Image-guided SBRT is a standard treatment for localized prostate cancer. This treatment uses imaging of the cancer within the body to define and localize the area to be treated with the radiation. Imaging can be obtained using either computed tomography (CT), magnetic resonance imaging (MRI), or a combination of the two. Typically, with SBRT, a radiation plan is developed based on the CT or MRI images obtained before treatment begins and adjustments are not made to the plan during treatment. However, anatomy can be different from day-to-day which may cause radiation to be delivered to the normal surrounding structures and possibly more side effects. During image-guided SBRT with online adaptation, the initial radiation plan is designed similarly; however, when the patient presents for radiation, the attending radiation oncologist, a dosimetrist, and a medical physicist "re-optimize" the radiation plan using the current anatomy of the day, meaning the changes in bladder and prostate size/shape are taken into account. The initial plan and the re-optimized plan are then compared, and the plan that has the optimal balance between delivering a tumor killing dose of radiation and minimizing radiation dose to normal surrounding structures is delivered. Image-guidance and online adaptation with SBRT may lower side effects and be a safer way to treat localized prostate adenocarcinoma.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial (MANTICORE) is studying an advanced form of stereotactic body radiation therapy (SBRT) — a highly precise, high-dose radiation — with real-time imaging adjustments to better treat localized prostate cancer while protecting nearby healthy tissue. **You may be eligible if...** - You are 18 or older - You have been diagnosed with prostate cancer that has not spread beyond the prostate or nearby lymph nodes - You have had appropriate staging tests (imaging, possibly bone scan or PET scan) - You are in reasonably good health (ECOG score 0–2) - You do not need urgent radiation treatment **You may NOT be eligible if...** - You have neuroendocrine or small cell prostate cancer - There is evidence of cancer that has spread to distant parts of your body - You have previously had prostate treatments such as cryotherapy, HIFU, brachytherapy, or pelvic radiation - You have Crohn's disease, ulcerative colitis, or ataxia telangiectasia Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo blood sample collection

PROCEDUREComputed Tomography

Undergo CT

RADIATIONCT-guided Stereotactic Body Radiation Therapy

Undergo CT-guided SBRT

OTHERInter-fraction Adaptation of Treatment Plan

Undergo daily plan adaptation

PROCEDUREMagnetic Resonance Imaging

Undergo MRI

RADIATIONMRI-guided Stereotactic Body Radiation Therapy

Undergo MRI-guided SBRT

OTHERSurvey Administration

Ancillary studies


Locations(1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07276438


Related Trials